Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05HOH
|
||||
| Former ID |
DNC013490
|
||||
| Drug Name |
Tyr-Sar-Phe-D-2-Nal-NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C34H37N5O5
|
||||
| Canonical SMILES |
CN(CC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC3=CC=CC=C3C=C2)C<br />(=O)N)C(=O)C(CC4=CC=C(C=C4)O)N
|
||||
| InChI |
1S/C34H37N5O5/c1-39(34(44)28(35)18-23-12-15-27(40)16-13-23)21-31(41)37-30(19-22-7-3-2-4-8-22)33(43)38-29(32(36)42)20-24-11-14-25-9-5-6-10-26(25)17-24/h2-17,28-30,40H,18-21,35H2,1H3,(H2,36,42)(H,37,41)(H,38,43)/t28-,29+,30-/m0/s1
|
||||
| InChIKey |
GNWOYARHUGPZGJ-JBOQNHBVSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. Epub 2008 Jan 8.Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.